Cytosorbents Corp (CTSO) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Cytosorbents reported revenue of $37.1M, up 4.1% from $35.6M the year before. Net income was -$8.2M (a -22.1% net margin), or -$2.60 per diluted share. Gross margin was 71.5% and operating margin was -39.8%. Operating activities generated -$12.4M of cash, leaving -$12.5M of free cash flow. At fiscal year end, Cytosorbents held $44.2M in total assets against $38.3M in total liabilities, including $6.2M of cash and equivalents.
Open the full interactive Cytosorbents financials → Quarterly statements, key ratios, valuation history and price charts.
Cytosorbents Key Stats
| Share Price | $3.46 |
|---|---|
| Market Cap | $10.9M |
| Revenue YoY Growth | +4.1% |
| 52-Week Range | $3.46 – $18.60 |
| Shares Outstanding | 3.1 million (basic, 2026 Q2) |
Cytosorbents Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $41.0M | $43.2M | $34.7M | $36.3M | $35.6M | $37.1M |
| Cost of Goods Sold | $11.1M | $11.0M | $14.0M | $14.0M | $10.5M | $10.6M |
| Gross Profit | $30.0M | $32.1M | $20.7M | $22.4M | $25.1M | $26.5M |
| Operating Income | -$10.4M | -$22.7M | -$31.5M | -$31.2M | -$16.8M | -$14.7M |
| Pre-Tax Income | -$9.0M | -$25.3M | -$33.9M | -$29.3M | -$22.4M | -$8.6M |
| Income Tax | -$1.1M | -$736,003 | -$1.1M | -$813,739 | -$1.7M | -$401,000 |
| Net Income | -$7.8M | -$24.6M | -$32.8M | -$28.5M | -$20.7M | -$8.2M |
| Diluted EPS | -$4.00 | -$11.40 | -$15.00 | -$12.80 | -$7.60 | -$2.60 |
Cytosorbents Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $9.5M | $9.2M | $8.9M | $9.6M |
| Net Income | -$3.2M | -$5.5M | -$5.1M | -$4.4M |
| Diluted EPS | -$1.00 | -$0.09 | -$1.60 | -$1.40 |
Cytosorbents Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $71.4M | $52.1M | $22.1M | $14.1M | $3.3M | $6.2M |
| Current Assets | $82.5M | $64.3M | $33.8M | $25.7M | $21.6M | $20.6M |
| Total Assets | $90.0M | $89.5M | $63.2M | $53.3M | $47.4M | $44.2M |
| Current Liabilities | $10.2M | $13.7M | $9.7M | $14.5M | $9.8M | $9.7M |
| Total Long-Term Debt | — | — | $5.0M | $5.0M | $14.0M | $16.7M |
| Total Liabilities | $10.7M | $26.9M | $27.9M | $30.0M | $36.3M | $38.3M |
| Shareholders' Equity | $79.2M | $62.6M | $35.4M | $23.3M | $11.1M | $5.9M |
Cytosorbents Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$5.6M | -$14.0M | -$28.2M | -$21.7M | -$14.4M | -$12.4M |
| Cash From Investing | -$1.7M | -$4.3M | -$6.5M | -$936,236 | -$669,430 | -$415,000 |
| Cash From Financing | $66.3M | $715,199 | $5.0M | $14.5M | $9.3M | $9.3M |
| Free Cash Flow | -$6.3M | -$17.6M | -$34.3M | -$22.2M | -$14.7M | -$12.5M |
Figures from Cytosorbents' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cytosorbents financials page for every line item.
Cytosorbents Company Profile
| Ticker | CTSO |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Princeton, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001175151 |
Frequently Asked Questions
What was Cytosorbents' revenue in fiscal 2025?
Cytosorbents (CTSO) reported revenue of $37.1M for fiscal 2025.
What is Cytosorbents' annual revenue history?
Cytosorbents' annual revenue by fiscal year: 2020: $41.0M; 2021: $43.2M; 2022: $34.7M; 2023: $36.3M; 2024: $35.6M; 2025: $37.1M.
What was Cytosorbents' net income in fiscal 2025?
Cytosorbents reported net income of -$8.2M for fiscal 2025.
What was Cytosorbents' earnings per share (EPS) in fiscal 2025?
Cytosorbents' diluted EPS was -$2.60 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Cytosorbents generate in fiscal 2025?
Cytosorbents generated -$12.5M of free cash flow in fiscal 2025.
What was Cytosorbents' revenue last quarter?
In its most recent reported quarter (2026 Q2), Cytosorbents reported revenue of $9.6M.
How much debt does Cytosorbents have?
Cytosorbents reported $16.7M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Cytosorbents are outstanding?
Cytosorbents reported a weighted average of 3.1 million basic shares outstanding in 2026 Q2.
What is Cytosorbents' market cap?
Based on its latest closing price, Cytosorbents (CTSO) has a market capitalization of about $10.9M.
When does Cytosorbents' fiscal year end?
Cytosorbents' fiscal year end, as registered with the SEC, is December 31.
Where is Cytosorbents headquartered?
Cytosorbents lists its business address in Princeton, New Jersey in its SEC filings.
Cytosorbents Competitors & Similar Companies
See all 109 Surgical & Medical Instruments & Apparatus companies →